AbbVie Company Profile (NYSE:ABBV)

About AbbVie (NYSE:ABBV)

AbbVie logoAbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:ABBV
  • CUSIP: 00287Y10
  • Web:
  • Market Cap: $105.14 billion
  • Outstanding Shares: 1,591,540,000
Average Prices:
  • 50 Day Moving Avg: $65.50
  • 200 Day Moving Avg: $63.22
  • 52 Week Range: $55.06 - $68.12
  • Trailing P/E Ratio: 17.12
  • Foreward P/E Ratio: 10.19
  • P/E Growth: 0.83
Sales & Book Value:
  • Annual Revenue: $26.22 billion
  • Price / Sales: 4.01
  • Book Value: $3.14 per share
  • Price / Book: 21.04
  • Annual Dividend: $2.56
  • Dividend Yield: 3.9%
  • EBIDTA: $11.15 billion
  • Net Margins: 23.22%
  • Return on Equity: 141.55%
  • Return on Assets: 12.64%
  • Debt-to-Equity Ratio: 5.76%
  • Current Ratio: 1.79%
  • Quick Ratio: 1.61%
  • Average Volume: 5.81 million shs.
  • Beta: 1.57
  • Short Ratio: 4.9

Frequently Asked Questions for AbbVie (NYSE:ABBV)

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Friday, February 17th. Investors of record on Thursday, April 13th will be paid a dividend of $0.64 per share on Monday, May 15th. This represents a $2.56 annualized dividend and a dividend yield of 3.88%. The ex-dividend date of this dividend is Tuesday, April 11th. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie announced that its Board of Directors has initiated a stock repurchase program on Sunday, April 9th 2017, which permits the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 5% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its stock is undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) issued its quarterly earnings results on Thursday, April, 27th. The company reported $1.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.02. The company earned $6.54 billion during the quarter, compared to analyst estimates of $6.49 billion. AbbVie had a return on equity of 141.55% and a net margin of 23.22%. The business's revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.15 EPS. View AbbVie's Earnings History.

When will AbbVie make its next earnings announcement?

AbbVie is scheduled to release their next quarterly earnings announcement on Thursday, July, 27th 2017. View Earnings Estimates for AbbVie.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY17 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $5.44-5.54 for the period, compared to the Thomson Reuters consensus estimate of $5.49.

Where is AbbVie's stock going? Where will AbbVie's stock price be in 2017?

15 equities research analysts have issued 1-year price targets for AbbVie's stock. Their forecasts range from $60.00 to $90.00. On average, they expect AbbVie's share price to reach $72.21 in the next year. View Analyst Ratings for AbbVie.

What are analysts saying about AbbVie stock?

Here are some recent quotes from research analysts about AbbVie stock:

  • 1. Jefferies Group LLC analysts commented, "ABBV's IPR with CHRS will be heard this week, which looks challenging in light of the prior institution decision. However, the market already expects ABBV to lose and we do not see the '135 patent alone as critical to delaying biosimilars, indicating positive asymmetry in our view. We look at the key IPR arguments as well as the risk/ reward around the decision expected in May as we prepare to attend the hearing." (2/14/2017)
  • 2. According to Zacks Investment Research, "AbbVie’s key drug Humira has been performing well and sales should continue to be driven by growing awareness, favorable clinical data, additional indications and expansion into new markets. Moreover, products like Viekira and Imbruvica have diversified AbbVie’s revenue base. Imbruvica has multi-billion dollar potential and AbbVie is exploring the potential to expand Imbruvica’s label into solid tumors and autoimmune diseases. AbbVie has a deep and promising pipeline and is also working on expanding its portfolio though additional deals. However, Viekira is facing intense pricing pressure and competition in the HCV market. Additionally, quite a few companies are working on bringing Humira biosimilars to market. Amgen’s biosimilar version of Humira received FDA approval in Sep 2016. Abbvie could see some of its dominant share in the arthritis market contract when Amgen’s new drug is launched." (9/28/2016)
  • 3. Argus analysts commented, "strong" second quarter earnings print.The analysts noted that not only were AbbVie's results driven by sales of Humira and Imbruvica, but its pipeline also "strengthened" following the acquisition of Stemcentrix and a partnership with Boehringer Ingelheim for the commercial rights of a new immunology drug that is in a late stage trial.The analysts also stated that the earnings print confirmed Imbruvica's "rapid acceptance" which bodes well for future sales. Coupled with the Venclexta drug, AbbVie boasts two "powerful drugs" to treat first- and second-line CLL and other hematogical malignancies.Related Link: Investors Cheer AbbVie's Q2 Numbers, ForecastThe analysts also stated that AbbVie's stock is "attractively valued" at just 11.2x their 2017 earnings per share estimate, which is "well below" the average multiple of 14.5 of other companies under Argus' coverage.Finally, the analysts boosted their full-year 2016 adjusted earnings per share estimate to $4.84 from $4.80 and their 2017 earnings per share estimate to $5.95 from $5.90."The company has strengthened its product portfolio and pipeline through several deals over the past 12 months, and continues to post strong sales of Humira, aided by new indications," (8/8/2016)

Are investors shorting AbbVie?

AbbVie saw a decline in short interest in May. As of May 15th, there was short interest totalling 30,327,253 shares, a decline of 7.1% from the April 28th total of 32,651,310 shares. Based on an average daily trading volume, of 5,390,470 shares, the days-to-cover ratio is presently 5.6 days. Currently, 1.9% of the shares of the company are short sold.

Who are some of AbbVie's key competitors?

Who owns AbbVie stock?

AbbVie's stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (0.00%), BlackRock Inc. (0.00%), State Street Corp (4.58%), Bank of New York Mellon Corp (1.14%), Morgan Stanley (0.00%) and State Farm Mutual Automobile Insurance Co. (0.00%). Company insiders that own AbbVie stock include Carlos Alban, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Thomas A Hurwich, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Who sold AbbVie stock? Who is selling AbbVie stock?

AbbVie's stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Glenview Capital Management LLC, Bank of New York Mellon Corp, APG Asset Management N.V., Miller Howard Investments Inc. NY, Parametric Portfolio Associates LLC, Fayez Sarofim & Co and Atalanta Sosnoff Capital LLC. Company insiders that have sold AbbVie stock in the last year include Carlos Alban, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

Who bought AbbVie stock? Who is buying AbbVie stock?

AbbVie's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Vanguard Group Inc., Renaissance Technologies LLC, State Street Corp, Prudential Financial Inc., Swiss National Bank and Atlantic Trust Group LLC. View Insider Buying and Selling for AbbVie.

How do I buy AbbVie stock?

Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of AbbVie stock cost?

One share of AbbVie stock can currently be purchased for approximately $66.06.

Analyst Ratings

Consensus Ratings for AbbVie (NYSE:ABBV) (?)
Ratings Breakdown: 10 Hold Ratings, 4 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $72.21 (9.32% upside)

Analysts' Ratings History for AbbVie (NYSE:ABBV)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/26/2017Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
5/17/2017BMO Capital MarketsReiterated RatingMarket Perform$66.00LowView Rating Details
4/28/2017Deutsche Bank AGBoost Price TargetHold$64.00 -> $65.00LowView Rating Details
4/20/2017Leerink SwannSet Price TargetHold$71.00LowView Rating Details
3/22/2017Societe GeneraleUpgradeSell -> HoldLowView Rating Details
3/11/2017Goldman Sachs Group IncUpgradeBuy -> Conviction-Buy$74.00 -> $80.00N/AView Rating Details
12/8/2016William BlairReiterated RatingOutperform$76.00N/AView Rating Details
11/28/2016Citigroup IncDowngradeBuy -> Neutral$60.00N/AView Rating Details
10/31/2016Credit Suisse Group AGDowngradeOutperform -> Neutral$70.00 -> $60.00N/AView Rating Details
9/8/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$75.00 -> $73.00N/AView Rating Details
9/1/2016Raymond James Financial, Inc.Initiated CoverageOutperform$82.00N/AView Rating Details
8/8/2016ArgusReiterated RatingBuy$85.00N/AView Rating Details
8/2/2016Barclays PLCReiterated RatingEqual Weight$68.00N/AView Rating Details
6/8/2016Morgan StanleyDowngradeOverweight -> Equal Weight$73.00 -> $65.00N/AView Rating Details
6/6/2016Cowen and CompanyDowngradeOutperform -> Market Perform$77.00 -> $70.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$59.00N/AView Rating Details
7/24/2015Evercore ISIReiterated RatingBuy$70.00N/AView Rating Details
7/22/2015SunTrust Banks, Inc.Initiated CoverageBuy$85.00N/AView Rating Details
6/17/2015Piper Jaffray CompaniesInitiated CoverageOverweightN/AView Rating Details
(Data available from 5/28/2015 forward)


Earnings History for AbbVie (NYSE:ABBV)
Earnings by Quarter for AbbVie (NYSE:ABBV)
Earnings History by Quarter for AbbVie (NYSE:ABBV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/2017Q1 2017$1.26$1.28$6.49 billion$6.54 billionViewN/AView Earnings Details
1/27/2017Q416$1.20$1.20$6.92 billion$6.78 billionViewListenView Earnings Details
10/28/2016Q316$1.21$1.21$6.55 billion$6.43 billionViewListenView Earnings Details
7/29/2016Q216$1.20$1.26$6.20 billion$6.43 billionViewListenView Earnings Details
4/28/2016Q116$1.14$1.15$6.03 billion$5.96 billionViewListenView Earnings Details
1/29/2016Q415$1.12$1.13$6.41 billion$6.36 billionViewListenView Earnings Details
10/30/2015Q315$1.08$1.13$5.90 billion$4.94 billionViewListenView Earnings Details
7/24/2015Q215$1.06$1.08$5.60 billion$5.48 billionViewListenView Earnings Details
4/23/2015Q115$0.85$0.94$718.50 million$5.04 billionViewListenView Earnings Details
1/30/2015Q414$0.86$0.89$5.34 billion$5.45 billionViewListenView Earnings Details
10/31/2014Q3$0.77$0.89$4.82 million$5.02 millionViewListenView Earnings Details
7/25/2014Q214$0.76$0.82$4.70 billion$4.93 billionViewListenView Earnings Details
4/25/2014Q114$0.68$0.71$4.33 billion$4.56 billionViewListenView Earnings Details
1/31/2014Q413$0.82$0.82$5.10 billion$5.11 billionViewListenView Earnings Details
10/25/2013Q313$0.78$0.82$4.52 billion$4.66 billionViewListenView Earnings Details
7/26/2013Q2 2013$0.79$0.92$4.54 billion$4.69 billionViewListenView Earnings Details
4/26/2013Q1 2013$0.67$0.68$4.17 billion$4.33 billionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for AbbVie (NYSE:ABBV)
Current Year EPS Consensus Estimate: $5.53 EPS
Next Year EPS Consensus Estimate: $6.48 EPS


Current Dividend Information for AbbVie (NYSE:ABBV)
Most Recent Dividend:5/15/2017
Annual Dividend:$2.56
Dividend Yield:3.88%
Dividend Growth:12.50% (3 Year Average)
Payout Ratio:70.52% (Trailing 12 Months of Earnings)
46.29% (Based on This Year's Estimates)
39.51% (Based on Next Year's Estimates)
Track Record:44 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for AbbVie (NYSE:ABBV)

Dividend History by Quarter for AbbVie (NYSE:ABBV)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for AbbVie (NYSE:ABBV)
Insider Ownership Percentage: 0.11%
Institutional Ownership Percentage: 66.67%
Insider Trades by Quarter for AbbVie (NYSE:ABBV)
Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)
Insider Trades by Quarter for AbbVie (NYSE:ABBV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/19/2017Richard A GonzalezChairmanSell71,235$65.49$4,665,180.15View SEC Filing  
5/18/2017William J ChaseCFOSell38,300$65.35$2,502,905.00View SEC Filing  
5/4/2017Carlos AlbanEVPSell43,000$67.00$2,881,000.00View SEC Filing  
3/10/2017Laura J SchumacherInsiderSell40,000$65.26$2,610,400.00View SEC Filing  
3/10/2017Robert A MichaelVPSell5,132$65.29$335,068.28View SEC Filing  
3/10/2017Timothy J RichmondSVPSell22,451$65.29$1,465,825.79View SEC Filing  
3/8/2017Richard A GonzalezChairmanSell72,016$64.25$4,627,028.00View SEC Filing  
12/2/2016William J ChaseCFOSell6,600$59.19$390,654.00View SEC Filing  
9/7/2016Laura J SchumacherInsiderSell50,000$65.00$3,250,000.00View SEC Filing  
6/24/2016Laura J SchumacherEVPSell186,106$60.03$11,171,943.18View SEC Filing  
6/2/2016Richard A GonzalezCEOSell285,953$63.82$18,249,520.46View SEC Filing  
5/11/2016Richard A GonzalezCEOSell39,000$63.80$2,488,200.00View SEC Filing  
5/10/2016Carlos AlbanEVPSell47,438$63.52$3,013,261.76View SEC Filing  
5/10/2016Thomas A HurwichVPSell6,000$63.59$381,540.00View SEC Filing  
5/10/2016Timothy J RichmondSVPSell21,583$63.52$1,370,952.16View SEC Filing  
3/8/2016Laura J SchumacherEVPSell25,000$56.09$1,402,250.00View SEC Filing  
3/1/2016Timothy J RichmondSVPSell12,866$55.05$708,273.30View SEC Filing  
4/28/2015Richard A GonzalezCEOSell102,964$64.67$6,658,681.88View SEC Filing  
3/2/2015Laura J SchumacherEVPSell25,000$60.30$1,507,500.00View SEC Filing  
3/2/2015Timothy J RichmondSVPSell14,388$60.33$868,028.04View SEC Filing  
12/22/2014William J ChaseCFOSell8,495$68.00$577,660.00View SEC Filing  
3/4/2014Richard GonzalezCEOSell4,799$51.20$245,708.80View SEC Filing  
3/3/2014Azita Saleki-GerhardtSVPSell2,443$50.25$122,760.75View SEC Filing  
3/3/2014Carlos AlbanEVPSell2,882$50.09$144,359.38View SEC Filing  
3/3/2014William ChaseCFOSell3,948$50.22$198,268.56View SEC Filing  
9/17/2013Azita Saleki-GerhardtSVPSell10,473$45.84$480,082.32View SEC Filing  
8/19/2013Azita Saleki-GerhardtSVPSell1,270$43.01$54,622.70View SEC Filing  
8/12/2013Azita Saleki-GerhardtSVPSell8,851$44.91$397,498.41View SEC Filing  
3/11/2013Edward J RappDirectorBuy2,500$37.67$94,175.00View SEC Filing  
2/4/2013Frederick H WaddellDirectorBuy2,000$37.05$74,100.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for AbbVie (NYSE:ABBV)
Latest Headlines for AbbVie (NYSE:ABBV)
DateHeadline logoAbbVie Inc (ABBV) Stock Rating Reaffirmed by Jefferies Group LLC - May 27 at 4:32 PM logoTop Presentations to Look for at ASCO - May 27 at 3:15 PM logoThe 2 Best Dividend Stocks in Marijuana - May 27 at 3:15 PM logoArt Levinson's Calico spots more space as it pounces on diseases of aging - May 27 at 1:12 AM logoBlog Coverage: Pfizer Cautions Shareholders Against Accepting TRC Capital Corporation's Mini-Tender Offer - May 26 at 3:08 PM logoBiogen's Fampyra Conditional Approval Converted to Standard - May 25 at 3:32 PM logoBig Pharma Has Big Catalysts Coming for the Rest of 2017 - May 25 at 3:32 PM logoBiogen's Fampyra Conditional Approval Converted to Standard - May 25 at 3:31 PM logoMajor Pharma Short Interest Surges - May 25 at 3:31 PM logoTestosterone Replacement Therapy (TRT) - Global Strategic Business Report 2017-2022 - Research and Markets - May 24 at 3:15 PM logoAbbVie Expects Rivals To Chip Away At Its Biggest Drug Franchise - May 24 at 3:15 PM logoAbbVie to Present at the Goldman Sachs 38th Annual Global Healthcare Conference - May 24 at 3:15 PM logoInsider Selling: AbbVie Inc (ABBV) Chairman Sells 71,235 Shares of Stock - May 23 at 7:26 PM logoRegeneron, Sanofi Undercut Amgen, AbbVie In Rheumatoid Arthritis - May 23 at 3:17 PM logoAbbVie's Phase 3 Failures Cast Dark Clouds - Seeking Alpha - May 22 at 3:16 PM logo Analysts Anticipate AbbVie Inc (ABBV) Will Post Quarterly Sales of $6.93 Billion - May 21 at 7:18 AM logoWilliam J. Chase Sells 38,300 Shares of AbbVie Inc (ABBV) Stock - May 19 at 7:40 PM logoZacks: Analysts Expect AbbVie Inc (ABBV) Will Post Earnings of $1.40 Per Share - May 19 at 10:30 AM logoAbbVie's Humira Loses Patent in Coherus' Petitions - May 19 at 9:50 AM logoAbbVie to Present at the Jefferies 2017 Global Healthcare Conference - May 19 at 9:50 AM logoAbbVie: 23 abstracts to be presented at ASCO - Seeking Alpha - May 18 at 3:15 PM logoAbbVie Inc (ABBV) Stock STILL Has Much More Room to Run Higher - - May 18 at 3:15 PM logoAbbVie Inc (ABBV) Stock STILL Has Much More Room to Run Higher - May 18 at 2:28 PM logoSPHD's Holdings Imply 10% Gain Potential - May 18 at 12:33 PM logoAbbVie to Present Latest Clinical Study Results in Hematology and Solid Tumor Research at the 53rd American Society of Clinical Oncology (ASCO) Annual Meeting - May 18 at 12:33 PM logoAbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : May 18, 2017 - May 18 at 12:33 PM logo[$$] AbbVie: It's the Pipeline, Not the Coherus Ruling - May 18 at 12:33 PM logoAbbVie (ABBV) Presents Phase 3 Data on Elagolix at World Congress on Endometriosis - May 17 at 3:17 PM logoAbbVie Declines After Humira Patent Loss - Seeking Alpha - May 17 at 3:17 PM logoAbbVie: Too Risky - Seeking Alpha - May 17 at 3:17 PM logoHumira Ruling Is A 'Big Victory' For Coherus - May 17 at 3:17 PM logoHumira Ruling Is A 'Big Victory' For Coherus - May 17 at 3:17 PM logoAbbVie's (ABBV) "Market Perform" Rating Reiterated at BMO Capital Markets - May 17 at 2:08 PM logoUS STOCKS-Futures slide as concerns over Trump spook investors - May 17 at 12:47 PM logoMorning Moves: Colgate, Target Climb; AbbVie Sinks; Disney Dips - May 17 at 12:47 PM logoAbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on Endometriosis - May 17 at 12:47 PM logoWhy This Humira Patent Loss Might Not Be What You Think - May 17 at 12:47 PM logoAbbVie's Humira patent loss not a death blow - May 17 at 11:07 AM logoCoherus BioSciences Prevails in ‘135 IPR Decision - May 16 at 8:17 PM logoCramer's lightning round: This car company's not encouraging you to buy stock - May 16 at 3:15 PM logoAbbVie (ABBV) Announce IMBRUVICA® (Ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies - May 16 at 5:28 AM logoCramer's lightning round: This car company's not encouraging you to buy stock - May 16 at 5:28 AM logoInvestors Purchase High Volume of AbbVie Call Options (ABBV) - May 15 at 6:14 PM logoTraders Purchase Large Volume of AbbVie Put Options (ABBV) - May 15 at 6:14 PM logoAbbVie's Revenue Growth Should Continue - Seeking Alpha - May 15 at 3:16 PM logoIMBRUVICA® (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) - May 14 at 8:17 PM logo3 Reasons To Prefer AbbVie Over Biogen - Seeking Alpha - May 12 at 1:30 AM logoAbbVie: Gross And Operating Margins Have Declined - Seeking Alpha - May 10 at 9:37 AM logo10-Q: NEUROCRINE BIOSCIENCES INC - May 9 at 8:17 PM logoAbbVie Announces Positive Phase 2 Study Results for Upadacitinib (ABT-494), an Investigational JAK1-Selective Inhibitor, in Crohn's Disease - May 9 at 3:16 PM



AbbVie (ABBV) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by Staff